Traws Pharma (TRAW) Cash from Financing Activities (2012 - 2026)
Traws Pharma (TRAW) posted quarterly Cash from Financing Activities of $1.9 million for Q1 2026, up 14492.31% year-over-year from N/an in Q1 2025, and up 1100.63% quarter-over-quarter from $158000.0 in Q4 2025.
Traws Pharma (TRAW) Cash from Financing Activities (2012 - 2026) Analysis & Trends
Traws Pharma (TRAW) has reported Cash from Financing Activities for 13 consecutive years, with $1.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 14492.31% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $5.1 million (down 74.5% YoY), while the FY2025 annual figure was $3.2 million, down 90.57% from the prior year.
- Cash from Financing Activities rose to $1.9 million in Q1 2026 per TRAW's latest filing, from $158000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $20.0 million in Q4 2024 and bottomed at -$62000.0 in Q3 2025.
- Historically, Cash from Financing Activities has averaged $4.2 million across 3 years, with a median of $1.0 million in 2025.
- Annual changes were most pronounced in 2025 — Cash from Financing Activities plunged 99.21% — and 2026, when it surged 14492.31%.
- Traws Pharma's Cash from Financing Activities stood at $20.0 million in 2024, then slumped by 99.21% to $158000.0 in 2025, then jumped by 1100.63% to $1.9 million in 2026.
- Business Quant data shows TRAW's Cash from Financing Activities at $1.9 million in Q1 2026, $158000.0 in Q4 2025, and -$62000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Traws Pharma | 5.66 Mn | 639,491.99 | - | 9.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.90 Mn |
| Mar 31, 2026 | 1.90 Mn |
| Dec 31, 2025 | 158,000.00 |
| Dec 31, 2025 | 158,000.00 |
| Sep 30, 2025 | -62,000.00 |
| Sep 30, 2025 | -62,000.00 |
| Jun 30, 2025 | 3.10 Mn |
| Jun 30, 2025 | 3.10 Mn |
| Mar 31, 2025 | 13,000.00 |
| Mar 31, 2025 | 13,000.00 |
| Dec 31, 2024 | 19.98 Mn |
| Dec 31, 2024 | 19.98 Mn |
| Dec 31, 2021 | -35,000.00 |
| Dec 31, 2021 | -35,000.00 |
| Sep 30, 2021 | 19.94 Mn |
| Sep 30, 2021 | 19.94 Mn |
| Jun 30, 2021 | 7,000.00 |
| Jun 30, 2021 | 7,000.00 |
| Mar 31, 2021 | 35.64 Mn |
| Mar 31, 2021 | 35.64 Mn |